In-vitro activity of avermectins against Mycobacterium ulcerans.
Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-03-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4351077?pdf=render |
id |
doaj-d5ebd057d10a43278211a48eb9951876 |
---|---|
record_format |
Article |
spelling |
doaj-d5ebd057d10a43278211a48eb99518762020-11-24T20:52:51ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352015-03-0193e000354910.1371/journal.pntd.0003549In-vitro activity of avermectins against Mycobacterium ulcerans.Till F OmansenJessica L PorterPaul D R JohnsonTjip S van der WerfYmkje StienstraTimothy P StinearMycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed minimum inhibitory concentrations of 4-8 μg/ml and time-kill assays using wild type and bioluminescent M. ulcerans showed a significant dose-dependent reduction in M. ulcerans viability over 8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that avermectins should be further evaluated for the treatment of BU.http://europepmc.org/articles/PMC4351077?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Till F Omansen Jessica L Porter Paul D R Johnson Tjip S van der Werf Ymkje Stienstra Timothy P Stinear |
spellingShingle |
Till F Omansen Jessica L Porter Paul D R Johnson Tjip S van der Werf Ymkje Stienstra Timothy P Stinear In-vitro activity of avermectins against Mycobacterium ulcerans. PLoS Neglected Tropical Diseases |
author_facet |
Till F Omansen Jessica L Porter Paul D R Johnson Tjip S van der Werf Ymkje Stienstra Timothy P Stinear |
author_sort |
Till F Omansen |
title |
In-vitro activity of avermectins against Mycobacterium ulcerans. |
title_short |
In-vitro activity of avermectins against Mycobacterium ulcerans. |
title_full |
In-vitro activity of avermectins against Mycobacterium ulcerans. |
title_fullStr |
In-vitro activity of avermectins against Mycobacterium ulcerans. |
title_full_unstemmed |
In-vitro activity of avermectins against Mycobacterium ulcerans. |
title_sort |
in-vitro activity of avermectins against mycobacterium ulcerans. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2015-03-01 |
description |
Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed minimum inhibitory concentrations of 4-8 μg/ml and time-kill assays using wild type and bioluminescent M. ulcerans showed a significant dose-dependent reduction in M. ulcerans viability over 8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that avermectins should be further evaluated for the treatment of BU. |
url |
http://europepmc.org/articles/PMC4351077?pdf=render |
work_keys_str_mv |
AT tillfomansen invitroactivityofavermectinsagainstmycobacteriumulcerans AT jessicalporter invitroactivityofavermectinsagainstmycobacteriumulcerans AT pauldrjohnson invitroactivityofavermectinsagainstmycobacteriumulcerans AT tjipsvanderwerf invitroactivityofavermectinsagainstmycobacteriumulcerans AT ymkjestienstra invitroactivityofavermectinsagainstmycobacteriumulcerans AT timothypstinear invitroactivityofavermectinsagainstmycobacteriumulcerans |
_version_ |
1716798787974856704 |